Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients
Theodore J. Cicero(Washington University in St. Louis), Peter W. Park(Pfizer (United States)), Jack Mardekian(Pfizer (United States)), Richard C. Dart(Washington Poison Center), Mario Mendoza(Pfizer (United States)), Carl L. Roland(Pfizer (United States)), Michael Polson(Magellan Health), Lynn R. Webster(Adherent Technologies (United States)), Sidney H. Schnoll(Virginia Commonwealth University Medical Center), Michael Cattaneo(Pfizer (United States))
Cited by 8
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304